These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32784684)

  • 1. Evaluating the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to High-Dose Trivalent and Other Egg-Based Influenza Vaccines among Older Adults in the US during the 2017-2018 Influenza Season.
    Pelton SI; Divino V; Shah D; Mould-Quevedo J; DeKoven M; Krishnarajah G; Postma MJ
    Vaccines (Basel); 2020 Aug; 8(3):. PubMed ID: 32784684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective cohort study assessing relative effectiveness of adjuvanted versus high-dose trivalent influenza vaccines among older adults in the United States during the 2018-19 influenza season.
    Pelton SI; Divino V; Postma MJ; Shah D; Mould-Quevedo J; DeKoven M; Krishnarajah G
    Vaccine; 2021 Apr; 39(17):2396-2407. PubMed ID: 33810903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017-18 influenza season.
    Divino V; Krishnarajah G; Pelton SI; Mould-Quevedo J; Anupindi VR; DeKoven M; Postma MJ
    Vaccine; 2020 Sep; 38(40):6334-6343. PubMed ID: 32739119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of high dose versus adjuvanted trivalent influenza vaccines in England and Wales.
    Mattock R; Gibbons I; Moss J; Mealing S; Largeron N; Carroll S; Alvarez FP
    J Med Econ; 2021; 24(1):1261-1271. PubMed ID: 34726129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019-20 Influenza Season-A Retrospective Cohort Analysis.
    Levin MJ; Divino V; Shah D; DeKoven M; Mould-Quevedo J; Pelton SI; Postma MJ
    Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance and value of adjuvanted influenza vaccine in the care of older adults from a European perspective - A systematic review of recently published literature on real-world data.
    Gärtner BC; Weinke T; Wahle K; Kwetkat A; Beier D; Schmidt KJ; Schwarz TF
    Vaccine; 2022 May; 40(22):2999-3008. PubMed ID: 35459556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018-19 Influenza Season in the United States.
    Krishnarajah G; Divino V; Postma MJ; Pelton SI; Anupindi VR; DeKoven M; Mould-Quevedo J
    Vaccines (Basel); 2021 Jan; 9(2):. PubMed ID: 33498724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly.
    Mullikin M; Tan L; Jansen JP; Van Ranst M; Farkas N; Petri E
    Infect Dis Ther; 2015 Dec; 4(4):459-87. PubMed ID: 26350238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany.
    Kohli MA; Maschio M; Cartier S; Mould-Quevedo J; Fricke FU
    Vaccines (Basel); 2022 Aug; 10(9):. PubMed ID: 36146464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative effectiveness of the adjuvanted vs non-adjuvanted seasonal influenza vaccines against severe laboratory-confirmed influenza among hospitalized Italian older adults.
    Domnich A; Panatto D; Pariani E; Napoli C; Chironna M; Manini I; Rizzo C; Orsi A; Icardi G;
    Int J Infect Dis; 2022 Dec; 125():164-169. PubMed ID: 36332902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cluster-randomized Trial of Adjuvanted Versus Nonadjuvanted Trivalent Influenza Vaccine in 823 US Nursing Homes.
    McConeghy KW; Davidson HE; Canaday DH; Han L; Saade E; Mor V; Gravenstein S
    Clin Infect Dis; 2021 Dec; 73(11):e4237-e4243. PubMed ID: 32882710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling the Economic Impact of lnfluenza Vaccine Programs with the Cell-Based Quadrivalent Influenza Vaccine and Adjuvanted Trivalent Influenza Vaccine in Canada.
    Nguyen VH; Roy B
    Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
    Vesikari T; Forstén A; Arora A; Tsai T; Clemens R
    Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating public health and economic benefits along 10 years of Fluzone® High Dose in the United States.
    Net P; Colrat F; Nascimento Costa M; Bianic F; Thommes E; Alvarez FP
    Vaccine; 2021 Mar; 39 Suppl 1():A56-A69. PubMed ID: 33509695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of MF59-adjuvanted and full-dose unadjuvanted trivalent inactivated influenza vaccines among vaccine-naïve children in a randomized clinical trial in rural Senegal.
    Diallo A; Victor JC; Feser J; Ortiz JR; Kanesa-Thasan N; Ndiaye M; Diarra B; Cheikh S; Diene D; Ndiaye T; Ndiaye A; Lafond KE; Widdowson MA; Neuzil KM
    Vaccine; 2018 Oct; 36(43):6424-6432. PubMed ID: 30224199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of the MF59-adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta-analysis.
    Coleman BL; Sanderson R; Haag MDM; McGovern I
    Influenza Other Respir Viruses; 2021 Nov; 15(6):813-823. PubMed ID: 34081398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effectiveness of Influenza Vaccines Among US Medicare Beneficiaries Ages 65 Years and Older During the 2019-2020 Season.
    Izurieta HS; Lu M; Kelman J; Lu Y; Lindaas A; Loc J; Pratt D; Wei Y; Chillarige Y; Wernecke M; MaCurdy TE; Forshee R
    Clin Infect Dis; 2021 Dec; 73(11):e4251-e4259. PubMed ID: 33211809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MF59-adjuvanted influenza vaccine (FLUAD®) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone®): A randomized, multicenter, Phase III pediatric trial in Mexico.
    Cruz-Valdez A; Valdez-Zapata G; Patel SS; Castelli FV; Garcia MG; Jansen WT; Arora AK; Heijnen E
    Hum Vaccin Immunother; 2018 Feb; 14(2):386-395. PubMed ID: 28925801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017-2018 and 2018-2019 Influenza Seasons.
    Boikos C; Fischer L; O'Brien D; Vasey J; Sylvester GC; Mansi JA
    Clin Infect Dis; 2021 Sep; 73(5):816-823. PubMed ID: 33605977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children.
    Nolan T; Bravo L; Ceballos A; Mitha E; Gray G; Quiambao B; Patel SS; Bizjajeva S; Bock H; Nazaire-Bermal N; Forleo-Neto E; Cioppa GD; Narasimhan V
    Vaccine; 2014 Oct; 32(46):6146-56. PubMed ID: 25223266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.